Alentis develops breakthrough treatments for fibrotic diseases. The pipeline includes specific antibodies against Claudin-1, a novel target in fibrosis and cancer. Unlike most therapies Alentis’ approach aims at a direct reversal of disease progression.

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business

You may also be interested in